Dana-Farber Cancer Institute | Strategic Alliance Partners

February 28, 2019

Yana Pikman, MD, a physician in the Cancer and Blood Disorders Center at Dana-Farber Cancer Institute and instructor of pediatrics at Harvard Medical School, discusses the implications of a matched targeted therapy approach in pediatric leukemia.

February 12, 2019

Suzanne George, MD, director of Clinical Research, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, and an associate professor of Medicine, Harvard Medical School, discusses ongoing trials in soft tissue sarcoma (STS).

February 06, 2019

Geoffrey R. Oxnard, MD, discusses the use of cell-free DNA as a potential method of cancer detection and subsequent assessment of treatment response in patients with solid and hematologic malignancies.

February 05, 2019

Because specific risk-reducing interventions may be available, it is important to identify individuals with germline variants in cancer susceptibility genes.

January 31, 2019

Huma Q. Rana, MD, discusses the evolution of genetic testing in ovarian cancer and the genes that are associated with an increased risk of subsequent cancer development.

January 29, 2019

Susana Campos, MD, MPH, highlights the success with PARP inhibitors in the relapsed and maintenance ovarian cancer settings.

January 29, 2019

Stephanie K. Dougan, PhD, discusses research aimed at assessing ways of augmenting T-cell immunity in pancreatic cancer.

January 25, 2019

Dana-Farber Cancer Institute researchers are Grand Challenge winners for a project that aims to discover how certain microbes inside the body lead to colorectal cancer and influence a patient’s response to treatment.

January 24, 2019

Neil Horowitz, MD, director of Clinical Research in Gynecologic Oncology, assistant professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Dana-Farber Cancer Institute, discusses frontline strategies in the treatment of patients with newly diagnosed advanced ovarian cancer.

January 24, 2019

Panagiotis A. Konstantinopoulos, MD, discusses the status of immunotherapy in ovarian cancer and focuses on numerous combinations under investigation.

January 23, 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses immunotherapy in the treatment of patients with renal cell carcinoma.

January 19, 2019

Stephanie K. Dougan, PhD, assistant professor, microbiology and immunobiology, Division of Immunology, Harvard Medical School, researcher, Dana-Farber Cancer Institute, discusses ways to extend the promise of immunotherapy to the field of pancreatic cancer.

January 17, 2019

Neil Horowitz, MD, discusses surgical options for patients with newly diagnosed ovarian cancer.

January 17, 2019

Panagiotis A. Konstantinopoulos, MD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the disappointing results of the JAVELIN 200 trial in ovarian cancer.

January 17, 2019

Suzanne George, MD, highlights the available therapies for patients with uterine sarcomas and what novel options are on the horizon.

January 16, 2019

Suzanne George, MD, assistant professor of Medicine, Harvard Medical School, clinical director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses the need for biomarkers in the treatment of uterine leiomyosarcoma.

January 12, 2019

Joyce F. Liu, MD, MPH, highlights the recent changes in the newly diagnosed ovarian cancer space and what the oncology field could see by the end of 2019.

January 11, 2019

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the use of immunotherapy in patients with recurrent ovarian cancer.

January 10, 2019

Suzanne George, MD, assistant professor of Medicine, Harvard Medical School, clinical director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses improving methods of diagnosis for women with uterine leiomyosarcoma.

January 09, 2019

Huma Q. Rana, MD, clinical director, Cancer Genetics and Prevention, instructor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses genetic testing guidelines for patients with ovarian cancer.